Chen, Hongan
McCann, Paul
Lien, Tiffany
Xiao, Mengli
Abraham, Alison G.
Gregory, Darren G.
Hauswirth, Scott G.
Qureshi, Riaz
Liu, Su-Hsun
Saldanha, Ian J.
Li, Tianjing
Funding for this research was provided by:
National Institutes of Health National Eye Institute (UG1EY020522, UG1EY020522, UG1EY020522, UG1EY020522, UG1EY020522, UG1EY020522)
Article History
Received: 1 June 2023
Accepted: 28 November 2023
First Online: 31 January 2024
Declarations
:
: Not applicable.
: Not applicable.
: HC has no conflicts of interest to report PM has no conflicts of interest to report TL has no conflicts of interest to report MX has no conflicts of interest to report AGA has no conflicts of interest to report DG has the following disclosures: Claris Biotherapeutics (I), Oyster Point Pharma (I), Sylentis (I)SH has the following disclosures: Allergan/Abbvie (C), BioTissue, Inc (C), Claris Biotherapeutics (I), TearScience, Inc (C), Johnson & Johnson Vision (C), Novartis (C), Sun Pharmaceuticals (C), TearRestore (C/I), Sight Sciences (C), Kala Pharmaceuticals (C), Dompe USA (C/I), Horizon Therapeutics (C), Science Based Health (C), Ocular Therapeutix (C/I), Nusight Medical (C), Oyster Point Pharma (C/I), Thea Pharma (C)RQ has no conflicts of interest to report SL has no conflicts of interest to report IJS has no conflicts of interest to report TL has no conflicts of interest to report C = paid consultant I = Investigator.